Literature DB >> 34169289

Protocol to establish a lung adenocarcinoma immunotherapy allograft mouse model with FACS and immunofluorescence-based analysis of tumor response.

Zhengxin Peng1, Man Yu1, Jiaming Lin1, Tianqi Dong1, Xiao Zhang1, Mingjun Shi1, Min Qin1, Shasha Li1, Wencong Guo1, Huixia Zhang1, Shuguo Sun1.   

Abstract

Anti-PD-1/PD-L1 therapy shows long-term effects in many cancer types, but resistance and relapse remain the main limitations of this therapy. Here, we describe a protocol to evaluate the tumor response to immunotherapy in a mouse lung cancer model. The protocol includes the establishment of the lung cancer mouse model, anti-PD-1 treatment, tumor-infiltrating lymphocyte isolation, immunofluorescence, and flow cytometry analysis. This protocol can also be applied to other cancer types and immunotherapies. For complete details on the use and execution of this protocol, please refer to Yu et al. (2021).
© 2021 The Author(s).

Entities:  

Keywords:  Cancer; Cell biology; Cell culture; Cell isolation; Flow cytometry/mass cytometry; Immunology; Microscopy; Model organisms

Mesh:

Year:  2021        PMID: 34169289      PMCID: PMC8209678          DOI: 10.1016/j.xpro.2021.100595

Source DB:  PubMed          Journal:  STAR Protoc        ISSN: 2666-1667


Before you begin

KrasLox-STOP-Lox(LSL)-G12D; Trp53flox/flox; ZsGreenflox/flox (KPZ) mouse preparation

Timing: 12 weeks Prepare 10 KPZ male mice at 6–8 weeks of age. Perform mouse crossing and breeding. Purchase the Kras P53, and Zsgreen mice from Jax lab. KPZ mice model is established by crossing KrasLox-STOP-Lox(LSL)-G12D, Trp53flox/flox and ZsGreenflox/flox mice. Finally, the mice is heterozygous for KrasLox-STOP-Lox(LSL)-G12D and homozygous for Trp53flox/flox and ZsGreenflox/flox. Expand 6v8 week-old male and female KPZ mice as the parents. F1 offsprings can be generated approximately 4 weeks later. Perform genotyping. Tail lysis. Add 200 μL 1× mouse tissue lysis buffer and 4 μL 10 mg/mL Proteinase K (Vazyme, CAT PD101-01) to the tail and incubate at 55°C for 12h Incubate at 95°C for 5 min and collect the supernatant by centrifugation at 140000 × g for 5 min at 25°C. Primers for Kras genotyping (from the Jackson Laboratory).

Avertin preparation

Timing: 2 days Prepare the stock solution (1.6 g/mL). Add 25 g 2,2,2-tribromoethanol (Avertin) and 15.5 mL tert-amyl alcohol in the dark. Stir on magnetic stirrer until the Avertin is dissolved (approximately 12 h). Avertin stock is light sensitive and hydroscopic and must be used away from light, and can be stored at 4°C for 1 year. Prepare the working solution (20 mg/mL). Mix 0.5 mL Avertin stock solution and 39.5 mL phosphate-buffered saline (PBS) in a glass vessel. Seal the container with parafilm, wrap in foil to avoid light and stir on a magnetic stirrer for approximately 12 h or until dissolved. Filter-sterilize the solution through a 0.22-μm filter and store at 4°C. The working solution can be aliquoted into 5-mL aliquots in sterile vials wrapped in foil or in a dark, capped bottle at 4°C for one year CRITICAL: Avertin should be stored in the dark!

Anti-PD-1 antibody preparation

Timing: 30min Prepare 1-mL aliquots immediately after receiving the anti-PD-1 antibody. The aliquots can be stored at −80°C for at least 1 year. Thaw the antibody on ice before use; note that the mice should be treated with the same antibody batch. Dilute the antibody to 1 mg/mL with PBS, and administer 200 μg antibody at a time per mouse.

Enzyme preparation

Timing: 1h Reconstitute DNase I and collagenase IV from lyophilized powders according to the manufacturer’s instructions. Reconstitute DNase I with PBS at a final concentration of 10 mg/mL and can be store at −20°C for at least 1 year. Reconstitute collagenase IV with PBS at a final concentration of 25 mg/mL, prepare 100 μL aliquots to avoid repeated freeze-thaw cycles, aliquots can be stored at −20°C for 1 year.

Preparation of cytokine stimulation reagents

Timing: 2h Prepare the cytokine stimulation reagents, phorbol 12-myristate 13-acetate (PMA), ionomycin, and Golgi inhibitor, at 1000 × concentrations. PMA is an analog of diacylglycerol, which is a key mediator in a variety of intracellular signaling pathways. Ionomycin can activate Ca2+-sensitive kinase to regulate gene expression. Brefeldin A which is the main effector of Golgi inhibitor can block intracellular protein transport processes. Together, these stimulation reagents lead to cytokine accumulation within the cell. Dissolve PMA in DMSO at a final concentration of 0.5 mg/mL, and prepare 10-μL aliquots to avoid repeated freeze-thaw cycles. The aliquots can be stored at −20°C for 1 year. Dissolve ionomycin in DMSO at a final concentration of 1 mM, prepare 10 μL aliquots. The aliquots can be stored at −20°C for 1 year. Golgi inhibitor (Brefeldin A) obtained from BD Biosciences is used according to the manufacturer’s instructions. Prepare 10-μL aliquots. The aliquots can be stored at −20°C for 1 year.

Key resources table

Materials and equipment

DMEM complete medium The medium can be stored at 4°C for 1 month. RPMI 1640 complete medium The medium can be stored at 4°C for 1 month. PEI solution Prepare 1 mL aliquots, the aliquots can be stored at −20°C for 1 year.

Step-by-step method details

KrasLox-STOP-Lox(LSL)-G12D;Trp53flox/flox; ZsGreenflox/flox mouse model

Timing: 8 weeks This section describes how to induce autochthonous tumors in genetically engineered mouse models (GEMMs). Package lentivirus. HEK293T cell line is cultured and maintained in 10 cm petri dish using 10 mL DMEM (GIBCO) supplemented with 10% Fetal Bovine Serum (FBS, HyClone) and 100 U/mL penicillin-streptomycin (GIBCO) at 37°C and 5% CO2 in a humidified Thermo fisher incubator. Produce lentivirus by cotransfecting 293T cells at 70%–80% confluency with 4 μg Lenti-LucOSCre(Addgene,#22777), 3 μg psPAX2 (Addgene, # 12260), and 1.5 μg pMD2.G (Addgene, # 12259)(DuPage et al., 2011). 1 μg/μL polyethylenimine (PEI) solution was used as transfection reagent, the transfection process are as follows. Mix the plasmids (9 μg in total) with 1 mL FBS free DMEM, stand for 5 min at 25°C. Add 27 μL (3 times the mass of plasmids) PEI solution to the plasmids-DMEM mixture, and stand for 15 min at 25°C. Add the transfection mixture to petri dish dropwise. Change medium within 18 h post transfection, given that viruses are produced around 18 h. Harvest supernatants containing viral particles 48 h after the medium change by collecting the supernatants in a 15-mL sterile tube. Keep everything on ice at all times. Pellet nonadherent cells and cell debris by centrifugation at 1600 × g at 4°C for 10 min and pass the supernatant through a sterile, 0.45-μM low-protein binding filter(Joshi et al., 2015). CRITICAL: To obtain high-quality lentivirus, HEK293T should be at rapid growth stage, and the cells should be transfected at 70%–80% confluency. Concentrate viral particles by ultracentrifugation. Transfer approximately 10 mL lentiviral supernatant to SW-41 ultracentrifuge tubes containing 1.5 mL of 20% sucrose cushion in PBS (w/v). Perform this step slowly to avoid mixing the layers. Bring a scale into the biosafety cabinet and balance the tubes in the metal bucket. by adding media with virus particles until the tubes are at no more than 0.01 g apart in weight and are filled until 2 mm from the top (also see Figure 6).
Figure 6

Lentivirus-sucrose cocktail in ultracentrifuge tube

Related to step 2b.

Concentrate lentiviral particles by centrifugation in an SW-41 rotor at 100000 × g for 2 h at 4°C (the virions will be in the pellet at the bottom of the tube). Remove the supernatant carefully! Resuspend the pellet in 200 μL of 1× HBSS buffer. Immediately titrate the samples and prepare 50 μL aliquots. The aliquots can be stored at −80°C for at least 1 years. Clean the biosafety cabinet with 10% bleach and then 70% EtOH. Treat the used pipettes and tips with 70% EtOH from biohazardous contamination. CRITICAL: This whole process should be performed on ice to maintain the viability of virus. Concentrated virus should be stored at −80°C in single-use aliquots to avoid freezing and thawing (Troubleshooting 1). Lentivirus titration Titrate lentivirus using the qPCR Lentivirus Titration Kit following the manufacturer’s instructions: https://www.abmgood.com/qpcr-lentivirus-titration-titer-kit-lv900-vin.html For functional titration, titrate lentiviruses expressing Cre by infecting the CAG-Loxp-mCherry-Loxp-ZsGreen cell line (termed the Cre reporter). Seed 1×104 Cre reporter cells with 100 μL DMEM complete medium in a 96-well plate. Serially dilute the virus 10-fold and replace the medium with 100 μL diluted virus. Count the number of ZsGreen-positive cell colonies 3 days after the medium change. Use the two smallest colony numbers to calculate the titer with the following formula: titer = (smallest colony number × dilution rate + the second smallest colony number × dilution rate) ×100/2 TU/mL. Lung Intratracheal intubation (also see the Methods video S1) Sedate a Kras;Trp53; ZsGreen mouse (6–8 weeks of age) by intraperitoneal injection of Avertin (female 0.4 mg/g, male 0.45 mg/g of body weight). While anesthesia sets in, prepare the catheter for intubation. First, blunt the needle of the catheter by cutting the end with scissors. Then, push the catheter completely over the end of the needle. Confirm the appropriate level of anesthesia by pedal reflex via firm toe pinching. Fix the mouse on the intubation platform by hooking its upper incisors over a suture and confirm that the chest is vertical underneath the suture. Place a fiber optic cable between the front legs to illuminate the chest. Carefully open the mouth of the mouse and pull out the tongue using disinfected flat forceps. Look for the emission of white light to locate the larynx and visualize the epiglottis and arytenoid cartilages. Once the opening of the trachea is clearly visible, gently slide the catheter into the trachea. The length of the catheter to be inserted depends on the age and size of the animal, since it should not go below the bifurcation to guarantee an even distribution of lung adenocarcinoma cells within the lung. Quickly remove the needle from the catheter. The proper placement of the catheter in the trachea is indicated by white light shining through the catheter. To confirm the placement of the catheter in the trachea, attach a 1-mL syringe containing water to the catheter. The water in the syringe will rapidly move up and down in accordance with the breathing. Pipette 50 μL of the suspension containing 105–106 TU virus per mouse into the center of the catheter hub. The suspension should be aspirated immediately. Subsequently, attach a 1-mL syringe and dispense 300 μL of air to ensure a consistent distribution within the lungs. Gently remove the catheter, remove the mouse from the intubation platform, and place it on a heat pad until it recovers from anesthesia. Ten weeks later, sacrifice the mice and isolate the lungs with adenocarcinoma for histological examinations and Tumor derived cell line (TDCL) establishment. CRITICAL: To ensure that tumors are evenly distributed in the lung, viruses should be evenly distributed within the lungs. We recommend dispensing 300 μL of air to the trachea after pipetting the virus. The concentration of virus and the time should be recorded (Troubleshooting 2).

TDCL cell line establishment

Timing: 4 weeks This section describes how to establish a mouse tumor cell line derived from GEMMs. Culture primary tumor tissue. Wash fresh lung tumor tissue with PBS containing 1% penicillin and streptomycin and mince the tissue into approximately 1-mm diameter pieces with scissors. Digest the minced tumor tissue with 1 mL 0.25% trypsin–EDTA for 15 min at 37°C. Remove cell aggregates and tissue fragments with a 70-μm cell strainer. Collect the cells by centrifugation for 5 min at 200 × g, remove the supernatant, resuspend 10000 cells with 500 μL RPMI-1640 complete medium, seed 500 μL cell suspension in 24 well culture plates. Maintain the cells in 500 μL RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin-streptomycin at 37°C in a humidified atmosphere of 5% CO2. Refresh the tissue culture medium every three days. Isolate single-cell clones. Trypsinize subconfluent cell monolayers with 100 μL 0.05% trypsin–EDTA for 2 min at 37°C. Count the cells, dilute cells to 80 cells per 10 mL and seed 100 μL into 96 wells plates. Culture the cells for 14 days and pick individual colonies using microscopy.

Mouse subcutaneous allograft injection

Timing: 25 days This protocol describes how to establish the subcutaneous allograft mouse model and monitor tumor growth in vivo using mouse tumor cells derived from GEMMs. Expand the cells. Seed TDCL cells in 10cm well 24 h before transplantation at approximately 50% confluency in RPMI-1640 complete medium. Incubate the cell cultures at 37°C, 5% CO2, and approximately 95% relative humidity. On the next day, harvest the cells using 1 mL of trypsin-EDTA (0.05% in PBS) at 37°C for 5 min per 10-cm plate and, subsequently, resuspend the detached cells with 9 mL of RPMI-1640 complete medium. Count the cells in a hemocytometer and transfer the number of cells needed for the experiments in a 50-mL conical centrifuge tube. Subsequently, centrifuge the cells for 5 min at 300 × g, aspirate the supernatant, and, using a pipette, resuspend the cells at a density of 7.5 × 106/mL (for the injection of 1.5 × 106 TDCL cells per mouse) in PBS. Keep the cells on ice until transplantation. Perform subcutaneous injection. Prepare C57BL/6 male mice at the age of 6–8 weeks. Mix the cell suspension and subcutaneously implant 200 μL of the suspension containing 1.5 × 106 cells (the number of cells may vary) in the right flank of each mouse. Once the tumor volume reaches 50–100 mm3 (6–8 days), randomly separate the tumor-bearing mice into two groups. We recommend using mice of the same genetic background and sex as the donor of tumor cells to guarantee the recipient mice tolerant well to the tumor cells. Measure the tumor volume. Determine the tumor volumes by measuring the length (l) and width (w) with a Vernier caliper every other day and calculating the volume with the formula (V = 0.5 × l × w2). At the end of the experiment (approximately 25 days), the mice are sacrificed, and tumors are isolated by dissection, weighed and used for in vitro experiments. The mean tumor diameter should not exceed 20 mm according to the tumor burden guideline.

Anti-PD-1 treatment

Timing: 3 weeks This section describes anti-PD-1 antibody treatment in tumor-bearing mice and how to monitor the tumor volume. We recommend using mice of the same sex and age to reduce individual differences. Intraperitoneally inject mice with 0.2 mg anti-PD-1 antibody(aPD-1) or Isotype control (IgG) 3 days after inoculation and treat every 3 days. Monitor the tumor volume with calipers every 2–3 days to ensure that the tumor volume does not exceed the ethical requirements for animal protection.

Tumor-infiltrating lymphocyte isolation

Timing: 1 day This step included dissection of the tumor tissue, dissociation of the tumor into single-cell suspension and lymphocyte isolation. We recommend using freshly isolated tumor tissue and that the processing time is minimal to ensure cell viability. Clean and sterilize surgical instruments, filters, and containers. Sacrifice the mice, dissect the tumors and carefully remove the skin. Cut 0.5 g tumor tissue for lymphocyte isolation, transfer the tumor tissue to a 50-mL tube with 1 mL FBS free DMEM and keep on ice till all the tumor tissue is dissected. It often takes 1 h for one person to dissect 10 mice. Gently cut the tumor into approximately 1-mm diameter pieces using scissors (perform this step within 2 min). Prepare the digestion solution Add 5 mL PBS to sterilized bottle. Add 50 μL 25 mg/mL Collagenase IV. Add 20 μL 1 mM DNase I. Mix well by shaking Add 5 mL digestion buffer to the 50-mL tube which containing tumor pieces, and incubate the sample in a shaker at 200 rpm for 1 h at 37°C. CRITICAL: This step should be performed very gently and quickly. Cell viability will decrease sharply if the procedure is too long. Note that the quality of collagenase is also crucial and determines the quantity and activity of cells. Obtain a single-cell suspension. Add 15 mL PBS to stop the digestion. Repeatedly pipette the tissue suspension with a dropper. Pass the tissue suspension through a 200-mesh filter and then collect the cell suspension. Lyse blood cells. Precool the centrifuge to 4°C. Centrifuge the cell suspension at 460 × g for 5 min to collect the cell pellet. Discard the supernatant, resuspend the cells in 1 mL ACK lysis buffer and place on ice for 1 min. Add 10 mL PBS to stop the lysis and centrifuge the cell suspension at 460 × g for 5 min. Prepare 40% (v/v) Percoll gradient solution. Add 6 mL serum free DMEM to a sterilized bottle. Add 0.4 mL 10 × PBS. Add 3.6 mL Percoll. Mix well by swirling. Discard the supernatant, resuspend the cells in 10 mL 40% (v/v) Percoll gradient solution, and centrifuge the cell suspension at 550 × g for 35 min. Carefully remove the supernatant, which contains a large number of tumor cells, with a dropper. The resulting cell pellet is enriched for lymphocytes. Resuspend the pellet in 10 mL PBS and centrifuge at 460 × g for 5 min to wash the cells. Discard the supernatant, resuspend the pellets in 1 mL DMEM containing 3% FBS, and count the living cells by trypan blue staining. Transfer equal numbers of living cells (5 × 106 is recommended) to 1.5-mL tubes for further flow cytometry analysis (Troubleshooting 3).

Flow cytometry analysis

Timing: 2 days Day 1 Prepare culture medium with cytokine stimulations reagents. Add 0.6 mL DMEM with 10% FBS. Add 0.6 μL 0.5 mg/mL PMA stock. Add 0.6 μL 1 mM Ionomycin stock. Add 0.6 μL golgi inhibitor stock. Mix well by vortexing. Centrifuge the lymphocytes at 460 × g for 5 min at 4°C, discard the supernatant and resuspend the cell pellets with 600 μL culture medium containing stimulations reagents. Transfer the cell suspension to a 24-well plate and incubate the cells in 5% CO2 at 37°C for 3 h. Stain for flow cytometry Allow lymphocytes to attach to the bottom of the plates, resuspend and transfer the cells to 96-well plates. Centrifuge the 96-well plate at 460 × g for 2 min at 4°C and discard the supernatant. The capacity of a 96 well is 300 μL; therefore, transfer the solution twice to collect all the cells. During centrifugation, prepare FACS buffer, which is 0.2% BSA (w/v) in PBS. Resuspend the cells in 200 μL FACS buffer, centrifuge the plate at 460 × g for 2 min at 4°C, and discard the supernatant. Prepare the antibody solution. Antibodies against Cell membrane markers Resuspend the cell pellets in 50 μL antibody and incubate the cells at 25°C for 15 min. Note that the following steps need to be performed away from light. Centrifuge the plate at 460 × g for 2 min and discard the antibody. Resuspend the cell pellets in 200 μL FACS buffer, centrifuge the plate at 460 × g for 2 min and discard the supernatant. Resuspend the cells in 150 μL fixation/permeabilization solution and fix the cells at 4°C for 40 min. Pause point: The fixed cells can be stored at 4°C for 24 h. Wash the cells with 200 μL FACS buffer, centrifuge and resuspend the cells in 200 μL FACS buffer. The next step can be performed on the second day. Day 2 Wash the cells with 200 μL of 1× perm/wash buffer, centrifuge the plate at 460 × g for 2 min, and discard the supernatant. Prepare the antibody solution. Cytokine antibodies Resuspend the cell pellets in 50 μL antibody solution and incubate the cells at 4°C for 1 h. Centrifuge the plates at 460 × g for 2 min, discard the antibody, and wash the cells with 200 μL FACS buffer. Centrifuge and resuspend the cells in 200 μL FACS buffer. Pass the cell suspension through a 200-mesh filter and analyze with a BD Verse cytometer. Refer to Figure 3 for the gating strategy. We recommend collecting 10,000 CD8+ T cells for further analysis (Troubleshooting 4).
Figure 3

Gating strategy for analysis of cytotoxic T lymphocyte (CTL) activity

Lymphocytes were initially gated by FSA and SSC (A), live gate to exclude viability dye positive dead cells (B), gated on CD45+, CD3+, CD8+ cells successively, CD8+ T cells defined as CD45+, CD3+, CD8+ cells (C and D), the IFN-γ+ cells and GZMB+ cells in CD8+ T cells were gated respectively (E and F).

Isotype control is recommended for cytokine staining, it helps you estimate the non-specific binding. For markers that are clearly bimodal, such as CD45 and CD8, there is no need to set up isotype controls.

Immunofluorescence analysis of CD8+ T cells

Timing: 2 days Day 1 This protocol describes how to process tumor tissue into slices and perform CD8+ T cell immunofluorescence to evaluate CD8+ T cell infiltration per tumor area. Embed the tissue. Fix the freshly isolated tumor tissues with 1% paraformaldehyde (PFA) at 4°C for 12 h. CRITICAL: For CD8 staining, the concentration of PFA is critical, and over 2% will result in a weak CD8 signal (Liu et al., 2015). Incubate the tissue with PBS (2 h), PBS with 15% sucrose (w/v) (2 h) and PBS with 30% sucrose (8 h) until the tissues are fully dehydrated. Place the dehydrated tissue in an embedding box, add OCT until the tissue is fully covered and seal the box. Incubate at 4°C for 12 h. Snap freeze the tissue. Obtain dry ice and transfer to a foam box; press the embedding box on the dry ice to create a box-shaped groove. Place the box with tissue into the groove and freeze for 20 min. Store the tissue at −20°C after OCT fully freezes. Obtain tissue sections. Cut the tissue into 5-μm-thick slices with a cryostat and transfer to a glass slide. Incubate the slices at 25°C for 2 h to dry. Store the slices at −20°C. Perform immunostaining of tissue sections. Add 500 μL PBS to the tissue section, let stand, and wash for 10 min. Discard the liquid by vacuum, draw lines on both sides of the tissue with a PAP pen, and wash with PBS again. Place the slices in a humidified box, add a drop of image enhancer (Invitrogen, CAT: I36933), and incubate at 25°C for 30 min. Rinse the slices with PBS and permeabilize with 0.3% (v/v) Triton X-100 in PBS (PBS-Triton) at 25°C for 30 min. Prepare the antibody solution; mix well by vortex. Immunofluorescence antibodies Add 100 μL antibody solution to the slice and incubate in a humidified box at 4°C for 12 h CRITICAL: Do not perform antigen retrieval as the CD8 signal will be completely lost. Day 2 Discard the antibody and rinse the slices with PBS-Triton four times. Add a drop of mounting medium, place the coverslip on the slices and seal with nail polish. Obtain whole tumor images by stitching images collected with a 10 X objective. Scan the sections by an Olympus FV3000 confocal system with a 60× silicone oil objective to get zoom in images. (Figure 5A). Troubleshooting 5
Figure 5

Analysis of CD8+ T cell infiltration by immunofluorescence

(A) Frozen sections of tumor tissue were stained for CD8 (green) and DAPI (blue). The whole tumor images were acquired by stitching images obtained using a 10 X objective (left panel), and the higher magnification images were scanned by a 60 X objective (right panel). Scale bars show 2,000 μm (left) and 50 μm (right).

(B) Analysis of CD8+ T cell infiltration of tumors that are sensitive to anti-PD-1 therapy, the values are calculated by counting total CD8+ T cell number/whole tumor area. n=5 for each group. Scale bar shows 50 μm. Data are mean ± SEM, two tailed T test. Figure reprinted with permission from Yu et al., 2021.

Western blot analysis

Timing: 2 days Lyse the tumor tissues. Homogenize and sonicate the tissue in 500 μL RIPA buffer in the presence of 1% (v/v) protease inhibitor cocktail and 2% (v/v) PMSF on ice. The freshly dissected tumor tissue can be stored at −80°C for few months. Centrifuge at 12,000 × g for 15 min at 4°C and collect the supernatant. Determine protein concentrations using the Pierce BCA Protein Assay Kit according to the manufacturer’s instructions: https://www.thermofisher.com/order/catalog/product/23227#/23227. Heat the protein at 98°C for 5 min with 4× loading buffer. Separate the sample by SDS-PAGE and transfer to PVDF membranes using the Trans-Blot Turbo Transfer System. Perform immunostaining. Block the membranes in 5% nonfat milk (Bio-Rad, USA) for 1 h at 25°C . Incubate the membranes with primary antibodies diluted in TBS-T (0.1% Tween) supplemented with 3% BSA at 4°C for 12 h. Wash the membranes with TBS-T 4 times. Incubate the membranes with fluorescent secondary antibodies for 1 h at 25°C. Wash the membranes and visualize the bands using the Odyssey CLx imaging system.

Expected outcomes

For lentivirus titration, the titer measured by qPCR should be similar to the functional titers (Figure 1).
Figure 1

Lentivirus titration method

(A and B). Titrate lentivirus using the qPCR Lentivirus Titration Kit following the manufacturer’s instructions. Amplification curve of qPCR (A). Example of titer calculation by Cq value (B).

(C and D). Titrate lentiviruses expressing Cre by infecting the CAG-Loxp-mCherry-Loxp-ZsGreen cell line. Representative images of infected cells in indicated well, dotted circle indicate one single colony (C, Scale bar show 100 μm). Functional titer calculation of virus from Figure 1B (D), note that Figure 1C are the representative images to show the cell colonies for counting, all the positive clones in one well should be counted as the colony number.

Lentivirus titration method (A and B). Titrate lentivirus using the qPCR Lentivirus Titration Kit following the manufacturer’s instructions. Amplification curve of qPCR (A). Example of titer calculation by Cq value (B). (C and D). Titrate lentiviruses expressing Cre by infecting the CAG-Loxp-mCherry-Loxp-ZsGreen cell line. Representative images of infected cells in indicated well, dotted circle indicate one single colony (C, Scale bar show 100 μm). Functional titer calculation of virus from Figure 1B (D), note that Figure 1C are the representative images to show the cell colonies for counting, all the positive clones in one well should be counted as the colony number. For KPZ model establishment, the tumor type should be adenocarcinoma according to tumor section (Figure 2).
Figure 2

Lung confocal section of KPZ mice at 10 weeks after lentivirus infection

Zsgreen showed tumor mass indicating tumor cells with Zsgreen (green) and the inserts show lower magnifications. Scale bars show 1,000 μm (left) and 100 μm (right). Figure reprinted with permission from Yu et al., 2021.

Lung confocal section of KPZ mice at 10 weeks after lentivirus infection Zsgreen showed tumor mass indicating tumor cells with Zsgreen (green) and the inserts show lower magnifications. Scale bars show 1,000 μm (left) and 100 μm (right). Figure reprinted with permission from Yu et al., 2021. For lymphocyte isolation, 1 × 107 cells can be obtained from 0.5 g tumor tissue, with over 70% living cells, of which lymphocytes account for approximately 30% (Figure 3). Gating strategy for analysis of cytotoxic T lymphocyte (CTL) activity Lymphocytes were initially gated by FSA and SSC (A), live gate to exclude viability dye positive dead cells (B), gated on CD45+, CD3+, CD8+ cells successively, CD8+ T cells defined as CD45+, CD3+, CD8+ cells (C and D), the IFN-γ+ cells and GZMB+ cells in CD8+ T cells were gated respectively (E and F). For flow cytometry and immunofluorescence analysis, if the tumor is sensitive to immunotherapy, the frequency of GZMB+ cells in CD8+ T cells, the frequency of IFN-γ+ cells in CD8+ cells (Figure 4) or CD8+ T cell infiltration (Figure 5B) may be significantly increased, indicating upregulated cytotoxic T lymphocyte activity.
Figure 4

Analysis of CTL activity in tumors that are sensitive to anti-PD-1 therapy by flow cytometry

Representative images of flow cytometry analysis of CD8+, GZMB+, and IFN-γ+ Cells in TDCL tumors, CD45+ cells were isolated from subcutaneous primary tumor tissues (A), plots showing the mean percentage ± SEM of CD8+ T cells in CD45+ cells, GZMB+ cells, and IFN-γ+ cells in tumor treated with IgG and aPD-1(n=6 for each group), two-tailed t test (B). Figure reprinted with permission from Yu et al., 2021.

Analysis of CTL activity in tumors that are sensitive to anti-PD-1 therapy by flow cytometry Representative images of flow cytometry analysis of CD8+, GZMB+, and IFN-γ+ Cells in TDCL tumors, CD45+ cells were isolated from subcutaneous primary tumor tissues (A), plots showing the mean percentage ± SEM of CD8+ T cells in CD45+ cells, GZMB+ cells, and IFN-γ+ cells in tumor treated with IgG and aPD-1(n=6 for each group), two-tailed t test (B). Figure reprinted with permission from Yu et al., 2021. Analysis of CD8+ T cell infiltration by immunofluorescence (A) Frozen sections of tumor tissue were stained for CD8 (green) and DAPI (blue). The whole tumor images were acquired by stitching images obtained using a 10 X objective (left panel), and the higher magnification images were scanned by a 60 X objective (right panel). Scale bars show 2,000 μm (left) and 50 μm (right). (B) Analysis of CD8+ T cell infiltration of tumors that are sensitive to anti-PD-1 therapy, the values are calculated by counting total CD8+ T cell number/whole tumor area. n=5 for each group. Scale bar shows 50 μm. Data are mean ± SEM, two tailed T test. Figure reprinted with permission from Yu et al., 2021. Lentivirus-sucrose cocktail in ultracentrifuge tube Related to step 2b.

Quantification and statistical analysis

For flow cytometry data, the frequency of each population is calculated by FlowJo software. Immunofluorescence images are analyzed using Cellsens software. The value is calculated by calculating the total CD8+ T cell number/whole tumor area.

Limitations

While these models are of particular value to investigate fundamental processes in lung tumor development, they require extensive mouse breeding, and the experiments are time-consuming. The tumor size and the number of infiltrating lymphocytes affect the cell yield, and tumors less than 0.2 g is hard to finish the analysis with enough lymphocytes. We recommend treating until the tumor reaches 500 mm3. Immunofluorescence of CD8 can partially reflect T cell infiltration, but tumors are highly heterogeneous; thus, analyzing a single slice does not represent the whole tumor. We recommend cutting slices from 3 different layers of the tumor and averaging the numbers.

Troubleshooting

Problem 1

The lentiviral titer is not high enough (step 2).

Potential solution

There are many factors affecting the titer of the lentivirus, such as the quality of the HEK293T cells and transfection reagent and the purity of the plasmids. Therefore, the cells should be in good condition, the transfection reagent should be fresh and free of quality problems, the plasmid should be highly purified, and the sequence should be verified before transfection.

Problem 2

The KP mice do not form tumors after virus intubation (step 4). First, the genotype of the experimental mice should be verified before lung intratracheal intubation. Second, it is important to ensure that the virus is delivered to the trachea but not to the esophagus. To confirm the placement of the catheter in the trachea, a 1-mL syringe containing water is attached to the catheter. The water in the syringe will rapidly move up and down in accordance with the breathing. Finally, the titer and viability of the virus you used should not be too low, functional titer over 106 TU/mL is recommended.

Problem 3

The isolated lymphocytes are not enough, and the ratio of living cells is low (step 22). Ensure that all the processes are carried out on ice, the tumor tissue is stored in precooled DMEM while waiting, and the procedure is as short as possible. When cutting up the tissues, ensure that the tissue pieces are not too small. Use collagenase IV with high quality and prepare aliquots to avoid freeze-thaw cycles. The activity of collagenase is important.

Problem 4

Undesirable signal in FC (step 26). Proper controls can be set up for trouble shooting. First, isotype control can be used to detect non-specific binding, appropriate blocking step can be added before staining if the isotype group showing high background (e.g., FC-receptor blocking). In addition, optimize the amount of antibody used by titration assay can further reduce nonspecific binding. Second, using fluorescence-minus-one control (FMO) can provide information about the potential compensation problem.

Problem 5

No CD8 T cell signal in IF (step 29). CD8 antigen is sensitive to PFA fixation and antigen retrieval process. Fix the tissue with 1% PFA within 12 h is critical to achieve bright CD8 signal. In addition, we have also tested the CD4 staining condition, CD4 stained well in tissues fixed with 4% PFA for 24 h.

Resource availability

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Shuguo Sun (Shuguo@hust.edu.cn).

Materials availability

This protocol does not generate new materials.

Data and code availability

This paper did not generate any new datasets or code.
Primer nameSequence 5′-3′
K-RasG12D 22907TGTCTTTCCCCAGCACAGT
K-RasG12D 22908CTGCATAGTACGCTATACCCTGT
K-RasG12DLSL oIMR9592GCAGGTCGAGGGACCTAA TA
REAGENT or RESOURCESOURCEIDENTIFIER
Antibodies

Anti-mouse PD-1(Clone: RMP1-14)Bio X CellCat#BE0146; RRID: AB_10949053
Rat IgG2a isotype control, anti-trinitrophenol (Clone: 2A3)Bio X CellCat#BE0089; RRID: AB_1107769
Anti-CD8-AF647(Clone: 53-6.7)BioLegendCat#Cat#100724 RRID: AB_389326
Dye-eFluor 506eBioscienceCat#65-0866-14
anti-CD45-percp/Cy5.5(Clone 30-F11)BioLegendCat#103132 RRID: AB_893340
Anti-CD3-APC (Clone: 17A2)BioLegendCat# :100235 RRID: AB_2561455
Anti-CD8a-PE/Cy7 (Clone: 53-6.7)BioLegendCat#100722 RRID: AB_312761
Anti-IFNγ-Bv421 (Clone: XMG1.2)BiLegendCat#505830 RRID: AB_2563105
Anti-GZMB-FITC (Clone: GB11)BioLegendCat#515403 RRID: AB_2114575

Chemicals, peptides, and recombinant proteins

Collagenase IVInvitrogenCat#17104019
DNase IRocheCat#10104159001
PMASigmaCat#P8139
IonomycinPeproTechCat#5608212
Golgi inhibitorBD BiosciencesCat#554724
PercollGE HealthcareCat#17-0891-01
2,2,2-Tribromoethanol (Avertin)Sigma-AldrichCat#T48402
DMEMGibcoCat#11995
RPMI-1640GibcoCat#11875
Phosphate Buffered Saline (PBS)HyCloneCat#SH30256
Fetal Bovine Serum (FBS)HyCloneCat#SV30087.03
Penicillin-StreptomycinGibcoCat#15140-122
HBSSGibcoCat#14170146
Polyethylenimine (PEI)PolysciencesCat#22966
SucroseCoolaberN/A
Paraformaldehyde (PFA)ServicebioCat#G1101
Albumin Bovine (BSA)BioFroxxCat#4240
RIPA BufferBeyotimeCat#P0013B
Protease inhibitor cocktailRocheCat# 4693116001
PMSFBeyotimeCat# ST506
Trypsin-EDTAGibcoCat#25200056
ACK lysis bufferGibcoCat#A1049201
OCTSakuraCat#4583
DAPISigma-AldrichCat#D9542
tert-Amyl alcoholaladdinCat#B1714001
Tween-20Sigma-AldrichCat#P7949
Triton X-100Sigma-AldrichCat# X100

Critical commercial assays

image-iT Image EnhancerInvitrogenCat#I36933
One Step Mouse Genotyping KitVazymeCat#PD101-01
qPCR Lentivirus Titration KitabmCat#LV900
Fixation/permeabilization solutionBD BiosciencesCat#554722
Perm/Wash BufferBD BiosciencesCat#554723
BCA Protein Assay KitThermoCat#23227
4× loading bufferBio-RadCat#1610747

Experimental models: cell lines

Tumor-derived cell line (TDCL)This paperN/A
CAG-Loxp-mCherry-Loxp-ZsGreen cell lineThis paperN/A
HEK293TATCCKenneth Irvine lab

Experimental models: organisms/strains

Mouse: KrasG12D.LSL; P53fl/fl; ZsgreenLSLThis paperN/A
Mouse: KrasG12D.LSLThe Jackson LaboratoryJAX: 008179
Mouse:P53fl/flThe Jackson LaboratoryJAX: 008462
Mouse: ZsgreenLSLThe Jackson LaboratoryJAX: 007906
C57BL/6 mouseBeijing Vital River Laboratory Animal TechnologyN/A

Oligonucleotides

Forward Primer for K-RasG12D wildtype allele: TGTCTTTCCCCAGCACAGTThe Jackson LaboratoryPrimer ID: 22907
Common Primer for K-RasG12D allele: CTGCATAGTACGCTATACCCTGTThe Jackson LaboratoryPrimer ID: 22908
Forward primer for K-RasG12DLSL mutant allele: GCAGGTCGAGGGACCTAA TAThe Jackson LaboratoryPrimer ID: oIMR9592

Software and algorithms

Cellsenshttps://www.olympus-lifescience.com/en/software/cellsens/N/A
FlowJo V10BD BiosciencesN/A
GraphPad prism 7GraphPad SoftwareN/A

Recombinant DNA

Lenti-LucOSCreAddgeneAddgene #22777
psPAX2AddgeneAddgene #12260
pMD2.GAddgeneAddgene #12259

Other

0.22-μm filterMilliporeCat#SLGP033RB
0.45-μm filterMilliporeCat#SLHP033RB
70-μm cell strainerBD BiosciencesCat#352350
SW-41 ultracentrifuge tubeBeckman CoulterREF#344059
96-well plateNESTCat#701201
24-well plateNESTCat#702001
10 cm petri dishNESTCat#704004
200-mesh filterSolarbioCat#YA0949
BD Verse CytometerBD BiosciencesN/A
Embedding moldsThermoCat#1830
NX 50 CryostatThermoN/A
Mounting MediumBeyotimeCat#P0126
FV3000 confocal systemOlympusN/A
Trans-Blot Turbo Transfer SystemBio-RadN/A
CLx Imaging SystemOdysseyN/A

DMEM complete medium

ReagentFinal concentrationAmount
DMEM-500 mL
FBS10%56 mL
penicillin-streptomycin100 U/mL5.6 mL

The medium can be stored at 4°C for 1 month.

RPMI 1640 complete medium

ReagentFinal concentrationAmount
RPMI 1640-500 mL
FBS10%56 mL
penicillin-streptomycin100 U/mL5.6 mL

The medium can be stored at 4°C for 1 month.

PEI solution

ReagentFinal concentrationAmount
PEI1 μg/μL0.1 g
H2O-100 mL

Prepare 1 mL aliquots, the aliquots can be stored at −20°C for 1 year.

Antibodies against Cell membrane markers

AntibodyDilution rateAmount
FACS bufferN/A50 μL
Fixable Viability Dye -eFluor 5061:4000.125 μL
anti-CD45-percp/Cy5.51:2000.25 μL
anti-CD3-APC1:2000.25 μL
anti-CD8a-PE/Cy71:2000.25 μL

Cytokine antibodies

AntibodyDilution rateAmount
1×Perm/Wash BufferN/A50 μL
anti-IFNγ-Bv4211:2000.25 μL
anti-GZMB-FITC1:2000.25 μL

Immunofluorescence antibodies

AntibodyDilution rateAmount
0.3% PBS-TritonN/A100 μL
anti-CD8-Alexa Fluor 6471:2000.5 μL
DAPI (10 μg/mL)1:502 μL
  4 in total

1.  Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation.

Authors:  Man Yu; Zhengxin Peng; Min Qin; Yang Liu; Jingning Wang; Cai Zhang; Jiaming Lin; Tianqi Dong; Lulu Wang; Shasha Li; Yongqin Yang; Shan Xu; Wencong Guo; Xiao Zhang; Mingjun Shi; Huiming Peng; Xianwen Luo; Huixia Zhang; Li Zhang; Yan Li; Xiang-Ping Yang; Shuguo Sun
Journal:  Mol Cell       Date:  2021-02-18       Impact factor: 17.970

2.  Immune homeostasis enforced by co-localized effector and regulatory T cells.

Authors:  Zhiduo Liu; Michael Y Gerner; Nicholas Van Panhuys; Andrew G Levine; Alexander Y Rudensky; Ronald N Germain
Journal:  Nature       Date:  2015-11-25       Impact factor: 49.962

3.  Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.

Authors:  Michel DuPage; Ann F Cheung; Claire Mazumdar; Monte M Winslow; Roderick Bronson; Leah M Schmidt; Denise Crowley; Jianzhu Chen; Tyler Jacks
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 31.743

4.  Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses.

Authors:  Nikhil S Joshi; Elliot H Akama-Garren; Yisi Lu; Da-Yae Lee; Gregory P Chang; Amy Li; Michel DuPage; Tuomas Tammela; Natanya R Kerper; Anna F Farago; Rebecca Robbins; Denise M Crowley; Roderick T Bronson; Tyler Jacks
Journal:  Immunity       Date:  2015-09-01       Impact factor: 31.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.